Researchers expand the CRISPR genome engineering toolbox with transposase-assisted target-site integration (TATSI), a ...

How does CRISPR work, and why is editing human embryos so controversial? Explore the science, the risks, and the ethical debates surrounding Dr. He Jiankui’s gene-editing experiment.

Research analysts at William Blair issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Monday, December 9th. William Blair analyst S. Corwin ...

When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...

The era of artificial intelligence has already begun and we talk more about its risks than its possibilities. Can we allow ...

I am glad that these negative results are finally shared, as it helps prevent duplication of work and unnecessary suffering in laboratory animals.” ...

The new company has also raised $75 million that will support the development of epigenetic editing therapies for hepatitis B ...

With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...

Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

Using the gene editing tool CRISPR she’s altered the genetic make-up of a cow so that its offspring are exclusively male.

These firms – potential “monster” stocks for 2025 – are projected to achieve gains of up to 1,000%, presenting significant ...

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.